This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and their staff. Conversations focused on the life-saving work researchers do each and every day to bring new treatments and cures to patients. During their meetings, researchers shared their own personal stories about the motivation behind their research, and discussed the highs and lows of the drug development process.
Although there are nearly 7,000 medicines in development, only 10 to 12 percent of medicines that enter clinical trials are ultimately approved for use. The odds of getting a medicine from the lab to a patient are tough. Despite these odds, there’s also tremendous hope in the promise of the biopharmaceutical pipeline. Today, 74 percent of medicines in clinical development are potentially first-in-class medicines, meaning they represent a possible new pharmacological class for treating a medical condition. And in cancer alone, new treatment options are changing the trajectory of disease and there are now over 1,100 medicines and vaccines in development to treat the conditions which make up the disease.
America’s biopharmaceutical researchers work tirelessly to develop treatments that have never existed before. Beyond the scientific advances, the biopharmaceutical industry supports over 4.7 million high-skilled jobs and is the single largest funder of business research and development, higher than the National Institutes of Health.
By highlighting the research and scientific impact of the biopharmaceutical industry, these researchers brought to life the important work done across the country every day to provide patients with the hope for cures for even the most devastating diseases.
#DYK there are over 7,000 medicines in development around the globe? @PhRMA #GoBoldly pic.twitter.com/mSU6AvXlna
— EMD Serono (@EMDSerono) June 12, 2018
Every day, Hoosier scientists work hard to make strides to provide innovative treatments to patients. Today, I welcomed a few of them to my DC office. #EliLilly @LillyPad pic.twitter.com/CBzPRRFfZp
— André Carson (@RepAndreCarson) June 12, 2018
Every day, our scientists are making strides to provide innovative treatments to patients. Today, we’re heading to Capitol Hill to share the importance of our work with members of Congress. #GoBoldly #ScienceIsOurPassion pic.twitter.com/NTKWgnW1Ua
— Sanofi US (@SanofiUS) June 12, 2018
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Report: More than 1,300 medicines and vaccines in development to help fight cancer
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Rare Disease Day: Unmet need inspires innovation
ICYMI: Why 2017 medicine approvals matter
New report and event examine the new era of vaccines
A new era in cancer
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New Era of Medicine
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill